Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A critical appraisal
British Journal of Dermatology Jan 11, 2018
Thomson J, et al. - As a part of this trial, the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids (TCS) vs placebo with TCS were comparatively analyzed among adults with moderate-to-severe atopic dermatitis (AD). When compared with TCS alone, dupilumab plus TCS led to an improvement in the AD up to week-52. This treatment illustrated acceptable safety.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
